Skip to main content
An official website of the United States government

Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Please check the “Other Notices” tab on the NIH Guide for Grants and Contracts to see updates to NIH policies that ensure alignment with the Administration’s priorities.

Parent Announcements (For Unsolicited or Investigator-Initiated Applications)

Parent announcements are broad funding opportunities that applicants can use to submit investigator-initiated applications for a range of popular programs. These announcements do not specify any particular area of scientific interest. They simply provide the standard forms and instructions needed to apply. Parent announcements are open for up to three years and are typically reissued to ensure continuity. They use standard due dates with three application, review, and award cycles each year.

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Sort descending Program Official
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-25-075 (UH3 Clinical Trials Not Allowed) UH3 10/15/2026 Sudhir Srivastava, Ph.D., M.P.H.
Notice of Special Interest (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research NOT-CA-24-074 01/08/2027 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Cancer Prevention and Control Clinical Trials Grant Program PAR-25-167 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/08/2027
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-25-070 (R21 Clinical Trial Not Allowed) R21 Clinical Trial Not Allowed 01/08/2027 Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-25-069 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/08/2027 Edward Sauter, M.D., Ph.D.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis PAR-25-081 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/08/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H.
HEAL Initiative: Studies to Enable Analgesic Discovery RFA-NS-25-023 (R61/R33 - Clinical Trial Not Allowed) R61, R33 Clinical Trial Not Allowed 01/16/2027 Rachel Altshuler, Ph.D.
The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research PAR-24-153 (K12 Clinical Trial Optional) K12 Clinical Trial Optional 02/19/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer NOT-CA-22-085 05/08/2027
Notice of Special Interest (NOSI): Factors impacting how Time-Restricted Eating (TRE) influences cancer-related outcomes NOT-CA-24-073 05/08/2027 Edward Sauter, M.D., Ph.D.